alexa APOE Genotypes Predictcardiometabolic Outcomes In Individuals With Metformin And Metforminsulfonylurea Combination Therapy
ISSN: 2155-6156

Journal of Diabetes & Metabolism
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

5th World Congress on Diabetes & Metabolism
November 03-05, 2014 Embassy Suites Las Vegas, USA

Dharambir K Sanghera
ScientificTracks Abstracts: J Diabetes Metab
DOI: 10.4172/2155-6156.S1.026
Recent evidence suggests improved clinical outcomes with metformin in patients with type 2 diabetes (T2D) and heart failure. However, the role of anti-diabetic medications in response to APOE genotypes is less understood. The objectives of this investigations were: 1) to evaluate the distribution of APOE polymorphisms in a large diabetic cohort of the Asian Indian Diabetic Heart Study, 2) to evaluate the impact of APOE variants on quantitative risk factors of T2D and heart disease, and 3) to examine the role of APOE genotypes in response to anti-diabetic therapy. A total of 4,769 individuals (2,690 T2D cases and 2,079 controls) were included in this study.No significant difference in the distribution of APOε4 was observed among T2D cases and controls. However, APOε4 carriers had higher fasting glucose (p=0.021), higher diastolic blood pressure (DBP), higher LDL cholesterol (LDL-C) and lower HDL-C (p=0.031) compared to non-APOε4 carriers. Further stratification of data from diabetic patients by APOE genotypes and anti-diabetic treatments revealed a significant decrease in fasting glucose (p<0.0001), 2 h glucose (p<0.0001), systolic blood pressure (SBP) (p=0.007), DSP, and LDL?C (p<0.0001) among the APOε4 carriers compared to non-APOε4 carriers on metformin monotherapy. Similar improved clinical outcomes were observed in patients with metformin-sulfonylurea combination therapy (n=618). Our study suggests APOε4 to be a potential risk factor for cardiometabolic susceptibility in patients with T2D. Our findings also report significantly improved cardiometabolic outcomes among APOε4 carriers in response to metformin and metformin-sulfonylurea combination therapy. These findings warrant confirmation in a large independent datasets. This study was supported by NIH grants -R01DK082766 (NIDDK) and NOT-HG-11-009 (NHGRI), and VPR Bridge Grant (OUHSC).
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version